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Abstract
TIMP-2 protein has been intensively studied as a promising anticancer candidate agent, but the in vivo mechanism
underlying its anticancer effect has not been clearly elucidated by previous works. In this study, we investigated the
mechanism underlying the anti-tumor effects of a TIMP-2 fusion protein conjugated with human serum albumin (HSA/TIMP-
2). Systemic administration of HSA/TIMP-2 effectively inhibited tumor growth at a minimum effective dose of 60 mg/kg. The
suppressive effect of HSA/TIMP-2 was accompanied by a marked reduction of in vivo vascularization. The anti-angiogenic
activity of HSA/TIMP-2 was directly confirmed by CAM assays. In HSA/TIMP-2-treated tumor tissues, MMP-2 expression was
profoundly decreased without a change in MT1-MMP expression of PECAM-1-positive cells. MMP-2 mRNA was also
decreased by HSA/TIMP-2 treatment of human umbilical vein endothelial cells. Zymographic analysis showed that HSA/
TIMP-2 substantially decreased extracellular pro-MMP-2 activity (94–99% reduction) and moderately decreased active MMP-
2 activity (10–24% reduction), suggesting MT1-MMP-independent MMP-2 modulation. Furthermore, HSA/TIMP-2 had no
effect on in vitro active MMP-2 activity and in vivo MMP-2 activity. These studies show that HSA/TIMP-2 potentiates anti-
angiogenic activity by modulating MMP-2 expression, but not MMP-2 activity, to subsequently suppress tumor growth,
suggesting an important role for MMP-2 expression rather than MMP-2 activity in anti-angiogenesis.
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Introduction
Angiogenesis is a fundamental process comprising the de-
velopment of new blood vessels from preexisting vessels in
physiological and pathological conditions. Development of new
blood vessels is one predominant mode of tumor progression, thus
the therapeutic manipulation of angiogenesis has emerged as
a promising strategy for cancer treatment [1], [2], [3]. Although
tumor angiogenesis is a complex multistep process, the degrada-
tion of components of the extracellular matrix (ECM) by
proteolytic enzymes known as matrix metalloproteinases (MMPs)
represents a crucial stage [4]. Artificial inhibitors to control ECM
proteolysis in angiogenic tumors have been developed and
characterized in many laboratory and clinical trials [4], [5], [6].
However, human clinical trials of synthetic MMP inhibitors for the
treatment of cancers have failed to show therapeutic benefit in
humans [5]. As an alternative, natural inhibitors of MMPs (tissue
inhibitors of matrix metalloproteinases; TIMPs) have increasingly
attracted attention as promising anticancer candidate agents.
TIMPs have multiple functions in cell proliferation, migration,
apoptosis, and differentiation in addition to their MMP-inhibitory
activities [6], [7], [8]. TIMP-2, one of four TIMPs, is a key
regulator of, and potential therapeutic agent against, angiogenesis
and tumor progression [9]. Gene therapy studies using adenoviral
and retroviral delivery systems in tumors have demonstrated a role
for TIMP-2 in suppressing angiogenesis and subsequent tumor
progression in animal models [10], [11]. However, virus-mediated
TIMP-2 gene therapy in humans may limit its therapeutic
application due to safety concerns, including cytotoxicity and
immune responses, along with it being a possible causative agent of
cancer [12], [13].
TIMP-2, a non-glycosylated protein, can be expressed in
Escherichia coli, but this process often results in the formation of
insoluble protein aggregates as inclusion bodies. Following the
recovery process including denaturation and renaturation, one of
the critical points for achieving a biologically active protein,
TIMP-2 proteins are often obtained as misfolded, biologically
inactive molecules with three-dimensional structures different from
native protein, which may be due to the presence of incorrect 6-
disulfide bridges [14], [15]. Modified TIMP-2 proteins such as
Ala+TIMP-2 [16] and TIMP-2 chimera protein with mosaic
serine protease [17] have also been developed and revealed
a profound multi-functional mechanism of TIMP-2. However,
a lack of information persists concerning the mechanism of its
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35710anticancer effect in vivo. Recently, a TIMP-2 fusion protein with
human serum albumin (HSA/TIMP-2) was produced with high
yield from the yeast Saccharomyces cerevisiae and demonstrated an
inhibitory effect against tumor growth [18]. Furthermore, we have
demonstrated that HSA/TIMP-2 exhibits favorable pharmacoki-
netic properties in prostate tumor xenograft [19].
In this study, our goals were to investigate the precise role of
HSA/TIMP-2 in anti-tumor activity associated with angiogenesis
and further define in vivo molecular links between anti-angiogenesis
and the modulation of MMP-2. Our results show that HSA/
TIMP-2, which does not inhibit MMP-2 activity or MT1-MMP
expression in vivo, acts to promote anti-tumor and anti-angiogen-
esis activity through the downregulation of MMP-2 expression.
This study is the first report of the in vivo mechanism underlying
anti-tumor activity and anti-angiogenesis associated with MMP-2
modulation via TIMP-2 protein.
Materials and Methods
Cell culture
Rat prostate cancer MAT-LyLu (MLL) cells were kindly
supplied by JungHan Yoon (Hallym University, Korea) [20] and
were cultured in DMEM/F12 (Lonza, Walkersville, MD, USA),
containing 10% (v/v) fetal bovine serum (Hyclone, Logan, UT,
USA) with 100,000 U/L penicillin and 100 mg/L streptomycin
(Gibco BRL, Grand Island, NY, USA). To generate a luciferase-
expressing, stable MLL cell line, MLL cells were stably transfected
with a CMV promoter-driven firefly luciferase expression
construct (pcDNA3.1-Luc, a gift from Dr. Dongmin Kang, Ewha
University, Seoul, Korea) using Lipofectamine
TM (Invitrogen Co.,
Carlsbad, CA, USA). Cells were grown under hygromycin B
(Sigma, St. Louis, MO, USA) selection, and positive clones were
screened by bioluminescence, supplemented with 150 mg/mL D-
luciferin (Biosynth International, Inc., Naperville, IL). Three
clonal cell lines were initially selected, and the strongest bio-
luminescent derivative MLL cell line (MLL-Luc) was used in this
study. The cell lines were monthly checked by PCR detection of
mycoplasma contamination.
Human umbilical vein endothelial cells (HUVECs) were
provided by Dr. Kwon Soo Ha (Kangwon University, Korea)
[21] and cultured in growth medium 199 (Gibco-BRL), supple-
mented with 20% fetal bovine serum, 10 ng/mL human basic
fibroblast growth factor (bFGF; R&D Systems Inc., Minneapolis,
MN, USA), 100 U/ml penicillin, 100 mg/ml streptomycin and
5 U/ml heparin. Confluent HUVECs (passages 4–7) were used for
the experiments. All cell lines were cultured at 37uCi na n
atmosphere of 5% CO2.
In vitro and in vivo MMP-2 enzyme activity assay
MMP-2 activity was measured using a sensitive MMP-2 near-
infrared fluorescent (NIRF) probe as a MMP-2 substrate [22]. For
in vitro assay, inactive proMMP-2 (R&D Systems) was converted
into the active form by incubation with 2.5 mM p-aminophenyl
mercuric acid (Sigma) at 37uC for 30 min prior to use. HSA/
TIMP-2, MMP inhibitor (MMP I, Calbiochem, San Diego, USA),
or TIMP-2 were incubated in the reaction buffer (100 mM Tris,
5 mM CaCl2, 200 mM NaCl, and 0.1% Brij) containing 14 nM
MMP-2 NIRF probe and 14 nM activated MMP-2 for 40 min.
Changes in fluorescence intensity were measured using an IVIS-
200 imaging system (Xenogen Corporation, Alameda, CA).
In vivo MMP-2 enzymatic activity was analyzed according to the
method of Bremer et al. [23], with some modifications. Briefly,
when MLL tumor had grown to about 500 mm
3 in volume, MMP
I (50 nM), HSA/TIMP-2 (80 mg/kg), or PBS control was
intraperitoneally (ip) injected twice per day. Subsequently,
MMP-2 NIRF probe (100 nM) was intravenously administered
30 min after the second injection of MMP I or HSA/TIMP-2.
NIRF images were obtained 2 h after probe injection with
Xenogen Living ImageH software (Xenogen Corporation) as
described in a previous study [19].
Zymographic analysis
MMP-2 activity was analyzed by gelatin zymography according
to the method of Uemura et al. [24], with some modifications.
Briefly, HUVECs were grown to 70–80% confluence, washed
once with PBS, and incubated for 72 h in serum-free medium in
the presence of HSA/TIMP-2. The culture medium was
centrifuged (1,000 rpm, 5 min), and the supernatants were
subjected to gelatin zymography. Aliquots of the supernatants
(10 mL) were mixed with sample buffer and applied directly to
a 10% polyacrylamide gel containing 1 mg/mL gelatin and 0.1%
(w/v) SDS. After electrophoresis, the gels were soaked in
renaturing solution for 60 min and then incubated in developing
solution overnight for maximum sensitivity. The gel was stained
with 0.5% Coomassie blue G-250 (Thermo Scientific Co.,
Waltham, MA) for 30 min and destained until the bands could
be seen clearly.
Semi-quantitative analysis of mRNA levels
Total RNA and cDNA were prepared as described in our
previous study [25]. PCR was performed with 100 ng cDNA per
sample for MMP-2 and the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) to normalize the samples
using Taq DNA polymerase (Invitrogen) in a PCR machine (PC-
808, Astec, Japan). Primer sequences for human GAPDH were 59-
AGAAGGCTGGGGCTCATTTG-39 (sense) and 59-
GGGGCCATCCACAGTCTTC-39 (antisense), and the PCR
for GAPDH was performed for 5 min at 95uC followed by 27
cycles of 30 s at 94uC, 30 s at 56uC, and 1 min at 72uC as well as
a final elongation step for 10 min at 72uC. MMP-2 primers were
59-GTGCTGAAGGACACACACTAAAGAAGA-39 (sense) and
59-TTGCCATCCTTCTCAAAGTTGTAGG-39 (antisense) [26].
PCR conditions for MMP-2 were the same as described for
GAPDH except for the primer annealing temperature (58uC) and
the number of cycles (28 cycles). The amplification products of the
PCR were electrophoresed on a 1% agarose gel and visualized by
ethidium bromide staining. For quantification, the gels were
scanned by an imaging system (TFX-20M, Vilber-Lourmat,
France) and analyzed using the ImageJ program (open source
ImageJ software available at http://rsb.info.nih.gov/ij/).
Subcutaneous primary solid tumor model
Male Balb/c nude mice (Orient, Gyeonggi-do, Korea), 8–10
weeks old, were anesthetized by exposure to 1–3% isoflurane/O2
and administered 1610
5 MLL or MLL-Luc cells suspended in
50 mLsterilePBSbysubcutaneous(sc)injectionintothedorsalflank.
Tumor growth was monitored for 5 days after injection by in vivo
bioluminescence imaging (BLI) and external caliper measurements.




of the Korea Basic Science Institute (KBSI-AEC 1110).
Bioluminescence imaging
In vivo BLI was performed with an IVIS-200 imaging system
(Xenogen Corporation). Mice received the substrate D-luciferin by
ip injection at a dose of 150 mg/kg dissolved in Dulbecco’s PBS.
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onto a warmed stage. Imaging was performed for 1–3 min,
depending on the tumor size and time point. Generally, five mice
were imaged at one time. Regions of interest in the tumor were
quantified as photon flux (p/s) using Xenogen Living ImageH
software.
Chick chorioallantoic membrane (CAM) assay
Anti-angiogenic activity was determined using a CAM assay as
described previously [27]. Fertilized chicken eggs were incubated
at 38uC in an 80% humidified atmosphere. On day 8, filter disks
(0.5 cm in diameter) were loaded on the CAM. HSA/TIMP-2
(1 mg/dose) or the equivalent volume of PBS was deposited in the
center of the filter. Treatment was repeated daily for 3 days, and
CAM results were analyzed on the fourth day. Photos of each
CAM were taken under a stereomicroscope (Stemi 2000-C, Carl
Zeiss, Oberkochen, Germany) using a digital camera (G5 PC1049,
Canon, Japan). Angiogenesis was quantified by counting the
number of blood vessel branch points surrounding the filter disk; at
least 10 viable embryos were tested for each treatment.
Dynamic in vivo imaging of blood vessels
Images of peritumoral blood vessels in living prostate cancer
xenografts were obtained using intravital fiberoptic confocal
fluorescence microscopy (FCFM; CellvizioH system; Mauna Kea
Technologies, Paris, France) as described previously [28] and
analyzed with ImageCell software version 3.6.1 (Mauna Kea
Technologies). The maximum signal observed within each frame
was averaged across a large set of representative frames (minimum
10) to determine the fluorescence reading for each mouse
peritumoral blood vessel. For quantification, randomly selected
frames were inspected blindly under an LSM 5 Pascal confocal
fluorescent microscope (Carl Zeiss) using a fluorescein isothiocya-
nate (FITC) filter at 488 nm. The image was then analyzed using
Pascal imaging software (version 2.8 SP1) to measure the mean
fluorescent vascular density.
Immunohistochemical analyses
After euthanizing the mice 15 days after 80 mg/kg HSA/
TIMP-2 administration to prostate cancer xenografts, tumor
tissues were collected and fixed overnight in freshly prepared 4%
paraformaldehyde in PBS. Immunohistochemical analyses were
performed on 8-mm sections using monoclonal antibodies specific
for Ki-67 (1:500; Abcam, Cambridge, MA), active caspase-3
(1:500; Abcam), or MMP-2 (1:500; Santa Cruz Biotechnology,
Santa Cruz, CA) as described previously [29]. Slides were
developed in 3,39-diaminobenzidine tetrachloride (Sigma) as
a chromogenic substrate and then counterstained with Mayer’s
hematoxylin. Images were taken with a light microscope (Carl
Zeiss) equipped with a digital camera (DP71, Olympus, Japan)
connected to a PC monitor.
For immunofluorescence staining, the sections were stained with
monoclonal antibodies specific for PECAM-1 (1:50; BD Bios-
ciences, Transduction Laboratories, San Diego, CA, USA), MMP-
2 (1:200, Santa Cruz Biotechnology), or MT1-MMP (1:200;
Millipore, Billerica, MA) and subsequently exposed to Alexa 488-
labeled goat anti-rat antibody or 546-labeled goat anti-rabbit
antibody, or 633-labeled goat anti-mouse antibody (1:500;
Molecular Probes, Eugene, OR, USA). Sections were counter-
stained with Hoechst 33342 (1:3,000; Invitrogen). Fluorescence
signals were analyzed using a confocal laser scanning microscope
(LSM-5 and LSM System, ver. 3.98; Carl Zeiss).
Western blot analysis
Western blot analysis was carried out as described previously
[30], and protein concentrations were determined by a standard
protein assay (Bio-Rad, Hercules, CA). The primary antibodies
were specific for PECAM-1 (1:200; Santa Cruz Biotechnology),
MMP-2 (1:1,000; Santa Cruz Biotechnology), MT1-MMP (1:200;
Millipore), or actin (1:10,000; Sigma). Detection was carried out
using horseradish peroxidase-conjugated IgG (1:5,000; Santa Cruz
Biotechnology) and visualized using the ECL assay kit (Amersham,
Little Chalfont, Buckinghamshire, UK). The band intensities
obtained by western blot analysis were determined using the
ImageJ program.
Figure 1. HSA/TIMP-2 inhibits tumor growth in MLL prostate
cancer xenografts. (A) Representative optical images of prostate
cancer xenografts. PBS as a control or HSA/TIMP-2 was ip injected every
two days for 14 days, beginning 5 days after MLL-Luc cancer cell
injection when the average tumor photon count had reached
approximately 3.0610
6 p/s/cm
2/sr. (B) Quantification of biolumines-
cence imaging. Data are expressed as the fold change of photon flux (p/
s) compared with the control at day 0 and represent the mean 6 SEM
(n=10 per group);
#P,0.05 vs. control group on day 14 by one-way
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For all results, values are expressed as the mean 6 standard
error of the mean (SEM). Statistical analyses were performed using
the Student’s t test for comparisons of 2 groups and using one-way
or two-way ANOVA (Graphpad Software Inc version 3.05, San
Diego, CA, USA) for multigroup comparisons. Significance was
set at P,0.05.
Results
Anti-tumor activity of HSA/TIMP-2 in prostate cancer
xenografts
To quantify the inhibitory effect of HSA/TIMP-2 on tumor
growth with BLI, we used a luminescent cancer xenograft with
a rat prostate cancer MLL cell line stably expressing firefly
luciferase. HSA/TIMP-2 protein was ip injected into the MLL-
Luc prostate cancer xenografts every other day for two weeks
based on our previous pharmacokinetic results [19]. As shown in
Fig. 1, bioluminescence signal reached 3.9260.79610
7 p/s at day
14 after PBS injection in the control group, and significant
inhibition of tumor growth was observed in the 60, 80, and
100 mg/kg HSA/TIMP-2 treatment groups: 45.9%, 55.8% and
80.8%, respectively, as compared to control (Fig. 1B;
F(4.45)=13.69, P,0.0001, one-way ANOVA).
Anti-proliferation, no apoptosis effect of HSA/TIMP-2
Anti-tumor activity typically requires the coordinated action of
tumor cell anti-proliferation and apoptosis [31]. Accordingly, to
evaluate possible in vivo effects of HSA/TIMP-2 on apoptosis and
proliferation, immunohistochemical staining data from treatment
and control groups of tumor-bearing mice were compared. The
percentages of active caspase-3-positive cells (apoptotic cells) in
Figure 2. HSA/TIMP-2 inhibits tumor cell proliferation but not apoptosis in prostate tumors. (A) Representative immunohistochemical
images of Ki-67 and active caspase-3 immunohistochemistry. Tumor sections were obtained at 15 days after initial injection of 80 mg/kg HSA/TIMP-2
(n=4 per group). The representative images were taken at an original magnification of 2006. (B) Quantification of Ki67- and active caspase-3-positive
cells as expressed by the percentage of brown pixels per field. The quantitative data represent the mean 6 SEM (n=4 per group). Significant
difference compared to the control group:
*P,0.05 by Student’s t test. ns=non-significant.
doi:10.1371/journal.pone.0035710.g002
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and 10.8%, respectively, with no significant difference (Fig. 2B;
P=0.80vs.control),suggestingnoeffectofHSA/TIMP-2treatment
on the apoptotic status of tumor cells. However, HSA/TIMP-2
treatment had a significant anti-proliferation effect in tumor cells in
vivo.Strong immunostaining for Ki-67 wasobserved in tumors from
the control group, whereas weak and moderate staining, with
a 28.1% reduction in Ki-67 immunoreactivity, was found in the
HSA/TIMP-2-treated group (Fig. 2B; P,0.05 vs. control). Similar
to the anti-proliferation effect observed in vivo, decreased cell
proliferation was also found in cultures of HUVECs (Fig. S1).
In vivo anti-angiogenic activity of HSA/TIMP-2
Although HSA/TIMP-2 has been shown to have an inhibitory
effect on the formation of capillary-like phenotype in HUVEC
Figure 3. HSA/TIMP-2 inhibits angiogenesis in vivo. (A) Representative images of blood vessels in PBS (control, upper panel) or 1 mg/dose
HSA/TIMP-2-treated CAM (lower panel). (B) Quantification of CAM angiogenesis. Blood vessel number was quantified in a circular perimeter
surrounding the filter disk (n=10 per group). (C) Representative image of PECAM-1 blood vessel visualized by immunofluorescence staining. The
vascular density of control and HSA/TIMP-2-treated tumors was determined by staining frozen sections with anti-PECAM-1 antibody (green) followed
by Hoechst nuclear counterstaining (blue). Scale bar=50 mm. (D) Quantitative measurement of vascular density in the tissue sections determined by
calculating the mean pixel intensity of PECAM-1 fluorescence staining per that of Hoechst nuclear staining. (E) In vivo PECAM-1 protein expression
detected by western blot analysis of tumor lysates. (F) Quantification of band intensity normalized by ß-actin. All quantitative data except for CAM
assay represents the mean 6 SEM (n=4 per group). Significant difference compared to the control group:
**P,0.01 by Student’s t test.
doi:10.1371/journal.pone.0035710.g003
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is not known. Thus, we performed CAM assays to investigate the
anti-angiogenic activityofHSA/TIMP-2,whichdemonstratedthat
vascularizationoftheHSA/TIMP-2-treatedgroupwassignificantly
decreased by 47.7% compared with the control group (Fig. 3A, B;
P,0.01). In analyzing tumor vascularization by immunofluores-
cence staining for endothelial cell marker PECAM-1, the micro-
vesselsofHSA/TIMP-2-treatedtumortissuedemonstratedasignif-
icant 39.2% decrease in PECAM-1level compared with the control
group (Fig. 3C, D; P,0.01). Western blot analysis also revealed an
evenmoresevere76.3%reductionintheexpressionofPECAM-1in
the HSA/TIMP-2-treated group (Fig. 3E, F; P,0.01 vs. control).
Consistent with the observed decrease in PECAM-1 level, dynamic
in vivo imaging of the vasculature using FCFM revealed that the
relative FITC-stained vessel density significantly decreased by
50.8% in HSA/TIMP-2-treated group (Fig. S2; P,0.01 vs. control,
Video S1 and S2).
Regulation of MMP-2 and MT1-MMP expression by HSA/
TIMP-2
Given the in vivo anti-angiogenic activity of HSA/TIMP-2, we
explored the regulatory effects of HSA/TIMP-2 on MMP-2, a key
regulator of tumor angiogenesis known to be modulated through
an interaction with TIMP-2 [32], [33]. A similar decrease in
Figure 4. HSA/TIMP-2 inhibits MMP-2 expression independent of MT1-MMP expression. (A) Representative immunohistochemical images
of MMP-2. The images were taken at an original magnification of 2006. (B) Quantification of MMP-2 expression determined by the percentage of
brown pixels per field. (C) Representative RT-PCR images of MMP-2. HUVECs were treated with the indicated doses of HSA/TIMP-2 (lanes 2–4), and
RNA was isolated 48 h after treatment. (D) Quantification of band intensity normalized by GAPDH. The quantitative data represent the mean 6 SEM
of duplicate samples from three independent experiments. (E) Representative images of PECAM-1, MMP-2 and MT1-MMP detected by
immunofluorescence staining. Frozen sections of tumor tissues were triple-immunostained with anti-PECAM-1, anti-MMP-2 and anti-MT1-MMP
followed by Hoechst nuclear (DAPI, blue) counterstaining. Scale bar=20 mm. (F) Quantitative measurement determined by calculating the mean pixel
intensity of MMP-2 (red) or MT1-MMP (green) fluorescence staining per that of Hoechst nuclear staining (blue). All quantitative data represents the
mean 6 SEM (n=4 per group). Significant difference compared to the control group:
**P,0.01,
*P,0.05 by Student’s t test. ns=non-significant.
doi:10.1371/journal.pone.0035710.g004
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tumors by western blot analysis (Fig. S3A, B). In addition, RT-
PCR analysis showed that HSA/TIMP-2 treatment decreased
MMP-2 mRNA in a dose-dependent manner in HUVECs
(Fig. 4C, D).
To further identify whether the downregulation of MMP-2 in
endothelial cells is associated with MT1-MMP, which facilitates
peri/extracellular pro-MMP-2 activation, we performed triple-
fluorescence immunostaining for PECAM-1, MMP-2 and MT1-
MMP on tumor tissue. Quantitative analysis indicated that the
level of MT1-MMP in PECAM-1-positive blood vessels did not
significantly differ between control and HSA/TIMP-2-treated
tumors (P=0.918), which was confirmed by western blotting of
tumor lysates from the HSA/TIMP-2-treated group (Fig. S3C, D;
P=0.096). In contrast, consistent with previous results, MMP-2
level in PECAM-1-positive blood vessels was significantly de-
creased by 50.9% in the HSA/TIMP-2-treated group (Fig. 4E, F;
P,0.01 vs. control), indicating that inhibition of MMP-2 by HSA/
TIMP-2 is independent of MT1-MMP expression.
Effect of HSA/TIMP-2 on MMP-2 proteolytic activity in
HUVECs
The unexpected results on MT1-MMP expression led us to
investigate the modulation of MMP-2 activity. We compared the
effects of TIMP-2 and HSA/TIMP-2 on MMP-2 activity using
zymographic analysis of HUVEC-conditioned media. As shown in
Fig. 5A, TIMP-2 dose-dependently inhibited both pro-MMP-2
(72 kDa) and active MMP-2 (68 kDa) activity. However, the effect
of HSA/TIMP-2 on MMP-2 activity was represented by distinct
patterns in pro-MMP-2 activation. Pro-MMP-2 showed an
outright loss of activity even at the low dose of HSA/TIMP-2
(2.5 mM), showing a dramatic decrease of 93.9% compared to that
of control. Active MMP-2 activity was suppressed by HSA/TIMP-
2 treatment, which had a maximal effect of 23.8% inhibition at
2.5 mM and did not decrease further at higher doses of HSA/
TIMP-2 (Fig. 5B). This finding could be the result of unleashing
endogenous MT1-MMP to promote pro-MMP-2 activation. This
data support the in vivo evidence that HSA/TIMP-2 inhibited
tumoral angiogenesis through downregulated expression of MMP-
2, but not the modulation of MT1-MMP activity.
Lack of the effect of HSA/TIMP-2 on MMP-2 activity
The MMP-2 inhibitory activity of TIMP-2 is known to be lost
by modification of the N-terminal of TIMP-2 such as carbamyla-
tion [34] or addition of an extra Ala [16], [35]. To determine
whether the substitution of the TIMP-2 N-terminal with HSA
alters TIMP-2 inhibitory activity, we compared the activity of
HSA/TIMP-2 with TIMP-2 and an MMP inhibitor (MMP I)
using a near-infrared fluorescent (NIRF) probe [22]. As shown in
Fig. 6A, the NIRF probe demonstrated a strong fluorescent
intensity (1.0160.01610
8 p/s) after proteolytic activation by
MMP-2, and this intensity was reduced by 75.9% with 10 nM
TIMP-2 and by 69.4% with 15 nM MMP I pre-treatment as
compared to non-treatment. However, 30 nM HSA/TIMP-2
treatment did not decrease NIRF signal (data not shown), and high
doses of HSA/TIMP-2 barely inhibited NIRF signals by 18.2% at
5 mM and 39.9% at 50 mM compared to non-treatment. Thus, the
inhibitory activity of HSA/TIMP-2 on MMP-2 was 4 orders of
magnitude less than that of native TIMP-2 and MMP I.
Furthermore, consistent with in vitro results, 2 h after injection of
NIRF probe, HSA/TIMP-2-treated MLL-tumor xenografted
mice demonstrated no NIRF intensity change, whereas the
MMP I-treated group demonstrated NIRF intensity significantly
decreased by 21.7% compared with the control group (Fig. 6C;
F(1,24)=5.43, P,0.05, two-way ANOVA), providing further
Figure 5. HSA/TIMP-2 inhibits extracellular proteolytic activity of MMP-2. (A) Representative images of the gelatin zymographic analysis.
Culture media from HUVECs treated with TIMP-2 or HSA/TIMP-2 for 72 h were analyzed on a gelatin gel. Two forms of MMP-2 (latent form, 72 kDa;
activated form, 62 kDa) are presented. (B) Quantification of band intensity. Data are expressed as the percentage of band intensity normalized with
respect to the proliferation level (Fig. S4). The quantitative data represent the mean 6 SEM of duplicate samples from three independent
experiments.
doi:10.1371/journal.pone.0035710.g005
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proteolytic activity.
Discussion
In this study, we provide in vivo evidence for anti-tumor activity
linkedtoanti-angiogenesisbyHSA/TIMP-2andfurtherclarifythat
the anti-angiogenesis is associated with attenuated MMP-2
expression independent of MMP-2 activity as demonstrated by the
absence of effects on MT1-MMP expression and pro-MMP-2
activation.
Our data concerning the effects of HSA/TIMP-2 on in vivo
angiogenesis are in agreement with the earlier findings of a null-
MMP inhibitor form of TIMP-2 (Ala+TIMP-2) [16]. HSA/
TIMP-2 has no inhibitory effect on MMP-2 activity in vitro and in
vivo; nevertheless HSA/TIMP-2 demonstrated a prominent anti-
proliferation effect on tumor cells in cancer xenografts. HSA/
TIMP-2 also interferes with processes critical to angiogenesis such
as endothelial cell proliferation and capillary-like tube formation
[19], and thus shows in vivo anti-angiogenesis effects. Additionally,
we have verified that the anti-angiogenic activity is differentially
modulated by HSA/TIMP-2 treatment leading to downregulation
of MMP-2 transcript in HUVEC cells. This finding is consistent
with previous reports that MMP-2 deficiency by genetic ablation
or siRNA-based approaches results in reduced angiogenesis [36],
[37], [38]. Interestingly, however, HSA/TIMP-2 did not induce
downregulation of MT1-MMP expression in vivo. In the zymo-
graphic analysis, we found no inhibitory action of HSA/TIMP-2
on pro-MMP-2 activation, resulting in the sustained activity of
active MMP-2. These results suggest a disconnection between
anti-angiogenic activity and MMP-2 activity. This concept is
supported by our results showing no effect of HSA/TIMP-2 on
Figure 6. HSA/TIMP-2 does not inhibit MMP-2 activity. (A) In vitro MMP-2 inhibitory activity was measured by co-incubating with a MMP-2
NIRF probe and activated MMP-2 in the presence of TIMP-2, MMP-2 inhibitors, or HSA/TIMP-2, followed by fluorescence imaging with an IVIS-200
imaging system (top). The corresponding fluorescence intensity (p/s) was quantified in each sample from 3 independent experiments (bottom). A
reaction containing NIRF and MMP-2 was used as a positive control in this experiment (lane 4). (B) Representative whole-body NIRF images. NIRF
imaging of MLL tumor-bearing mice was performed at 2 h after injection of the MMP-2 NIRF probe in the presence of MMP I (n=4), HSA/TIMP-2
(n=5), or control PBS (n=6). (C) The quantitation of fluorescent signal in the tumor. The fluorescence intensity (p/s) was quantified based on the total
photon count determined from regions of interest. Each data point represents the mean 6 SEM;
#P,0.05 vs. control group by two-way ANOVA
followed by Bonferroni post-hoc test.
doi:10.1371/journal.pone.0035710.g006
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2-independent anti-angiogenic activity of TIMP-2 [16], [39].
Moreover, recent studies have demonstrated that the C-terminal
domain of TIMP-2, in particular loop 6, inhibits endothelial cell
proliferation and angiogenesis [40], suggesting a potential role of
the C-terminal domain of TIMP-2 in the anti-angiogenic activity
of HSA/TIMP-2.
Cancer development involves complex multistep processes, but
all cancers share the ability to proliferate beyond the constraints
limiting growth in normal tissue and to resist the intrinsic property
of self-destruction called apoptosis [41], [42]. Because deregulated
cell proliferation together with suppressed cell death provide
a common platform for tumor progression, they present targets for
cancer therapy [43]. Numerous studies have considered to these
two defects as cancer targets, whereas the effects of TIMPs on cell
proliferation or apoptosis have been restricted to cell-based
experiments and elicited divergent effects even in the same cell
types [44], [45], [46], [47]. Consistent with previous observations
in melanoma cells and human microvascular endothelial cells [47],
[48], [49], we demonstrated that cell proliferation was potently
downregulated in HSA/TIMP-2-treated tumor tissue as well as
HUVECs. In contrast, the effect of HSA/TIMP-2 on apoptosis
did not differ from control, which is contrary to the MMP-
independent proapoptotic effect of TIMP-2 described previously
[39], [50], [51]. This difference may be due to the differing ability
of HSA/TIMP-2 and TIMP-2 to regulate the expression of MMP-
2. With respect to the interaction of death pathways with MMP-2,
Shapiro et al. [52] demonstrated that active MMP-2 induces
apoptosis of endothelial cells via the p38 MAPK apoptotic
pathway, which enhances MMP-2 synthesis and its activation
probably through MT1-MMP. In contrast, Preaux et al. [53]
showed that apoptosis promotes pro-MMP-2 activation through
increased MT1-MMP expression. The relationship between
apoptosis and MMP-2 is controversial; however, our data support
the hypothesis that downregulation of MMP-2 expression by
HSA/TIMP-2 is associated with an attenuation of apoptosis.
Our finding that high doses of HSA/TIMP-2 protein inhibit
angiogenesis and subsequently inhibit tumor growth is consistent
with the findings of previous TIMP-2 studies [10], [11], [16], [54].
However, at lower doses (less than 40 mg/kg), HSA/TIMP-2
demonstrated a stimulative effect on prostate cancer xenografts
(data not shown). This difference may be explained by the bi-
functional activity of TIMP-2 in angiogenesis, as proposed by Seo et
al.[16]:lowlevelsofTIMP-2enhanceangiogenesisbytheactivation
of MMPs through an MT1-MMP-dependent mechanism, whereas
high levels of TIMP-2 downregulate angiogenic signaling through
binding to a3b1 integrin. Thus, our determination of the effective
dose for anti-tumor activity provides important information for
cancer therapies aimed at modulating angiogenesis.
In agreement with a previous study of B16BL6 melanoma
xenografts [18], systemic administration of HSA/TIMP-2 protein
also demonstrated a potent anticancer effect in MLL prostate
cancer xenografts. However, the minimum effective doses of the
two studies differ slightly. It was determined as 60 mg/kg in this
study, whereas tumor growth was suppressed at 40 mg/kg in the
B16BL6 melanoma xenograft model. This difference could be
explained by different experimental methods such as the number
of drug injections, the cancer cell line used for tumor xenografts,
and the detection method of tumor growth. In this study, we used
BLI analysis with a MLL bioluminescent xenograft model [55],
which has several advantages over traditional caliper measure-
ments including accurate monitoring of tumor growth as well as
earlier tumor detection as the tumor progresses. Traditional
volumetric analysis by caliper measurements inevitably counts
necrotic areas and edema as well as cancer cells in a tumor, but the
bioluminescence signals of BLI analysis are derived from only
viable cancer cells and thus exclude a systematic bias from the
inclusion of necrotic areas and edema [56], [57]. This different
sensitivity of detection methods may explain the different
minimum effective doses of the two studies, as a moderate
correlation was observed between tumor volume and photon flux
(R
2=0.89, Fig. S5). In addition to the detection method of tumor
growth, another explanation is the number of HSA/TIMP-2
administrations. HSA/TIMP-2 was injected every two days in this
study, whereas 40 mg/kg HSA/TIMP-2 was injected daily in the
B16BL6 melanoma xenograft study [18].
In conclusion, this study is the first to report that HSA/TIMP-2
has dose-dependent effects on tumor growth in male Balb/c nude
mice, highlighting the importance of minimum effective dose
determination on anti-tumor activity in vivo. We also demonstrate
that the anti-tumor activity of HSA/TIMP-2 is strongly associated
with anti-angiogenesis attributed to a reduction of MMP-2
production but without inhibition of MT1-MMP, indicating that
HSA/TIMP-2 plays a more complex role in anti-angiogenesis.
Taken together, these findings provide a useful basis for the in vivo
mechanistic study of TIMP-2 anti-tumor activity and suggest that
HSA/TIMP-2 holds promise as an anticancer drug.
Supporting Information
Figure S1 Effect of HSA/TIMP-2 on HUVEC prolifera-
tion. HUVECs were stimulated with 50 ng/mL bFGF followed
by treatment with 10 mM HSA/TIMP-2 for 48 h. Proliferation of
viable cells was assessed by WST-1 assay (Takara, Kyoto, Japan).
Results show the percentage of maximum proliferation obtained
by stimulation of cells with bFGF alone, after correction for the
basal rate of proliferation under serum-free conditions (100%).
The quantitative data represent the mean 6 SEM of triplicate
samples from three independent experiments. Significant differ-
ence compared to the control group:
**P,0.01 by Student’s t test.
***P,0.001.
(TIF)
Figure S2 Inhibitory effect of HSA/TIMP-2 on angio-
genesis in vivo. (A) In vivo images of peritumoral blood vessels
taken by FCFM imaging following intra-arterial injection of
75 mg/kg FITC-dextran. Representative images were captured at
an original magnification of 206. (B) The quantitative data from
the mean area of vessels represents the mean 6 SEM. Vessel area
was determined as the area stained with FITC-dextran. The
quantitative data represents the mean 6 SEM (n=4 per group).




Figure S3 HSA/TIMP-2 does not inhibit MT1-MMP
expression. (A) Detection of MMP-2 (72 kDa) protein expres-
sion by western blot analysis of tumor lysates. (B) Quantification of
band intensity normalized by ß-actin. (C) Detection of MT1-MP
(54 kDa) protein expression by western blot analysis of tumor
lysates. (D) Quantification of band intensity normalized by ß-actin.
All quantitative data represent the mean 6 SEM (n=4 per group).
Significant difference compared to the control group:
*P,0.05 by
Student’s t test. ns=non-significant.
(TIF)
Figure S4 Effect of TIMP-2 or HSA/TIMP-2 on HU-
VECs proliferation. HUVECs (5610
3/well) were plated in 96-
well plates and treated with TIMP-2 or HSA/TIMP-2 at the
indicated concentration for 48 h. Proliferation of viable cells was
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SEM of triplicate samples from three independent experiments.
(TIF)
Figure S5 Correlation between BLI and tumor volume
in vivo. (A) Image of MLL-Luc prostate cancer xenografts. MLL-
Luc cells (1610
5) were implanted into the dorsal flank by sc
injection. (B) Quantification of bioluminescence intensity and
tumor volume. BLI and caliper measurements (L6W
2/2) were
acquired at the indicated time point 5 days after implantation
(n=6). A moderate correlation between BLI (p/s, y-axis) and
tumor volume (mm
3, x-axis) was observed (R
2=0.89).
(TIF)
Video S1 Angiography of tumoral vessels. Intravital
fiberoptic confocal fluorescence microscopy of peritumoral vessels
in a MLL prostate cancer xenograft. Tumoral vasculature is
imaged after 75 mg/kg FITC-dextran injection (shown in green).
(MPEG)
Video S2 Angiography in HSA/TIMP-2-treated tumoral
vessels. Multiphoton intravital fiberoptic confocal fluorescence
microscopy of peritumoral vessels in a MLL cancer xenograft.
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